ABSTRACT
Pancreatic panniculitis represents a rare cutaneous disorder most commonly associated with acute or chronic pancreatitis or pancreatic carcinoma. We describe a case of a 17-year-old woman who presented with a 2-day history of erythematous patches involving her bilateral knees and tender, scattered red-brown nodules involving her bilateral anterior shins. She was seen during a hospitalization for emergent cesarean section and her hospital course was complicated by HELLP syndrome (defined by the presence of hemolysis, elevated liver enzymes, low platelet count), acute fatty liver of pregnancy and pancreatitis. The characteristic histopathologic findings, including ghost cells, fat necrosis and granular basophilic material with dystrophic calcification, appear in later lesions. In early lesions, as was shown in this case, a neutrophilic subcutaneous infiltrate raises a differential diagnosis including infection, subcutaneous Sweet's syndrome or atypical erythema nodosum. To our knowledge, this represents the first report of pancreatic panniculitis in association with HELLP syndrome and acute fatty liver of pregnancy. Early recognition is critical, as skin lesions may precede the development of pancreatitis. Often, as in our case, the effects of pancreatitis may be life threatening.
Subject(s)
Fatty Liver/pathology , HELLP Syndrome/diagnosis , Pancreas/pathology , Panniculitis/pathology , Pregnancy Complications/diagnosis , Acute Disease , Adolescent , Anti-Bacterial Agents/therapeutic use , Diagnosis, Differential , Erythema Nodosum/diagnosis , Female , HELLP Syndrome/drug therapy , Humans , Panniculitis/drug therapy , Pregnancy , Pregnancy Complications/drug therapy , Skin Diseases, Infectious/diagnosis , Sweet Syndrome/diagnosis , Treatment OutcomeABSTRACT
Major advancements in the realm of photoprotection have occurred over the last decade providing potential means to reduce the prevalence of ultraviolet radiation-related skin problems. This review elucidates current photoprotective methods and recent developments that may hold future promise.
Subject(s)
Chemoprevention/methods , Melanoma/prevention & control , Protective Clothing , Skin Neoplasms/prevention & control , Sunburn/prevention & control , Sunscreening Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antioxidants/therapeutic use , Camellia sinensis , Early Diagnosis , Health Education , Humans , Melanoma/diagnosis , Melanoma/epidemiology , Melanoma/etiology , Nursing Assessment , Plant Extracts/therapeutic use , Primary Prevention , Skin Neoplasms/diagnosis , Skin Neoplasms/epidemiology , Skin Neoplasms/etiology , Sunburn/complications , Ultraviolet Rays/adverse effects , United States/epidemiology , United States Food and Drug Administration , Vitamin A/therapeutic useABSTRACT
Erythema nodosum is an inflammatory reaction of the skin characterized by tender erythematous patches or nodules, usually located on the lower extremities. This report illustrates an association of erythema nodosum with a rare malignancy and an uncommon infectious agent in humans. There are many diseases associated with erythema nodosum; we propose that hairy cell leukemia and group C streptococcus be considered among this list.
Subject(s)
Erythema Nodosum/pathology , Leukemia, Hairy Cell/pathology , Panniculitis/microbiology , Panniculitis/pathology , Skin Neoplasms/pathology , Streptococcal Infections/diagnosis , Streptococcus/classification , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy, Needle , Erythema Nodosum/complications , Erythema Nodosum/diagnosis , Follow-Up Studies , Humans , Immunohistochemistry , Leg Dermatoses/complications , Leg Dermatoses/diagnosis , Leg Dermatoses/pathology , Leukemia, Hairy Cell/complications , Leukemia, Hairy Cell/drug therapy , Male , Severity of Illness Index , Skin Neoplasms/complications , Skin Neoplasms/drug therapy , Streptococcal Infections/complications , Streptococcus/isolation & purification , Treatment OutcomeABSTRACT
BACKGROUND: Extracorporeal photopheresis (ECP) has been used for nearly 20 years for the treatment of cutaneous T-cell lymphoma (CTCL). A substantial body of literature reports that this form of photoimmunotherapy improves or stabilizes the course of disease in a subset of patients across all stages. However, current clinical approach usually reserves ECP for patients who do not respond to other treatments or for patients with late-stage disease or Sézary syndrome (SS). METHODS: A comprehensive Pubmed/Medline literature search was performed to identify studies reporting the use and efficacy of ECP in early stage (IA, IB, and IIA) CTCL. Information regarding prognostic factors and survival of early-stage patients treated with ECP was also obtained and summarized. RESULTS: The heterogenous nature of the reports and lack of any prospective randomized trials made evaluation of response to treatment difficult. However, the current literature contains at least 124 early-stage patients treated with ECP or ECP plus adjuvant therapy from 1987-2007 in 16 different reports. Response rates of treatment for this patient population with ECP and ECP plus adjuvant therapy varied from 33-88%. CONCLUSIONS: Given the very low side effect profile of ECP compared with other therapies and its demonstrated efficacy, this treatment modality is possibly beneficial for patients with earlier stages of CTCL. Randomized prospective studies are needed to establish the role of ECP in this disease subset.